Briefing Jan 2026

Revenue-grade early warning.

Portfolio intelligence you can underwrite.

See operational risk before it reaches the ledger.

Standard Reporting
  • EBITDA within range
  • Covenants intact
  • No early alerts
Field Reality
  • FX bottlenecks at suppliers
  • Informal credit stacking
  • Inventory quality decay

This is where revenue leakage starts—before it shows up in NPL.

Risk Signal Extract
Live
Sector Pharmaceuticals
Type Supplier FX Stress
Visibility 90–120 days pre-ledger
Action Watchlist Recommended
Protect Revenue

Avoid surprise limit breaches.

Win Revenue

Pick winners 90 days early.

Improve Returns

Price risk with conviction.

The Ground-Truth Methodology

Triangulating financial forensics with field-level reality.

I
Pillar I

Financial Diagnostics

Focus

Detecting hidden balance sheet friction.

Action

Distinguish Revenue Drivers from "Zombie Assets".

II
Pillar II

Operational Verification

Focus

Physical verification of production and infrastructure.

Action

Calculate the Execution Gap between capacity and output.

III
Pillar III

Institutional Resilience

Focus

Auditing workforce stability.

Action

Verification of union friction and hidden liabilities.

IV
Pillar IV

ESG Mapping

Focus

Environmental risk impact on financing.

Action

Verification of waste management and energy efficiency.

Executive Chairman

Dr. Hossain Zillur Rahman

Leading the Editorial Board, Dr. Rahman ensures all intelligence meets the highest standards of institutional rigor.

Sector Domain Experts Senior Peer Reviewers
Validation

Roundtable Series

Findings stress-tested through closed-door sessions.

  • Policy Validation
  • Industry Stress-Tests
  • Academic Review
Proposal

The Recalibration

Sector Heatmap

Green/Amber/Red ratings for 30 key accounts.

Revenue Protection

Top 10 actions: limits, covenants, triggers.

Revenue Wins

Top 10 deployment targets gaining share.

Allocation Description Value (BDT)
Total Program Tier-Based Solvency Stress-Test & Diagnostic Suite 1,200,000
Bank Direct Cost Co-investment for Pharma Pilot mandate 700,000
Deferred Recovery Balance recovered via annualized subscription 500,000
Assessments are analytical judgments based on field data and sector validation.